InvestorsHub Logo

nidan7500

10/01/18 6:13 PM

#167347 RE: kevli33 #167337

Kevli33...Excellent...thanks for this link

Investor2014

10/01/18 6:28 PM

#167349 RE: kevli33 #167337

Great find thank you. A2-73 mentioned at 51:50.

“Trial also using a lot of fluid biomarkers”

dia76ca

10/01/18 6:58 PM

#167350 RE: kevli33 #167337

Great find kevli…..he referred to Anavex 2-73 trial as an important first step in application of precision medicine to Alzheimer's. And he was speaking in Spain...where the PD trial is using the precision medicine approach to PD. And in his talk he stressed the need for a broad application of genetic based precision medicine...not only to cancer but also to a wide range of CNS diseases. Very worthwhile to listen to. He saved discussion of the Anavex 2-73 trial to near THE END OF HIS TALK, TO SUM UP WHAT HE WAS IT WAS ALL ABOUT!

About 51:30

tredenwater2

10/01/18 11:36 PM

#167363 RE: kevli33 #167337

Thanks kevli. HH is doing some heavy lifting here IMo. Downplaying BIIB’s approach and supporting AVXL’s in a roundabout way. Wont be long now, partnership tied to trial starts and or FDA approvals will be in the Billions.


Tred

XenaLives

10/02/18 7:14 AM

#167367 RE: kevli33 #167337

Harald Hampel speaks again at the VI International Congress on Research and Innovation in Neurodegenerative Diseases: https://ciiien2018.org/

Anavex mentioned at 51:29, Hampel speaks in general about the shift to personalized medicine.


Thank you to Kevli33 for the original posting:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143918368&txt2find=hampel